SG11201502778TA - Method of prognosis and stratification of ovarian cancer - Google Patents
Method of prognosis and stratification of ovarian cancerInfo
- Publication number
- SG11201502778TA SG11201502778TA SG11201502778TA SG11201502778TA SG11201502778TA SG 11201502778T A SG11201502778T A SG 11201502778TA SG 11201502778T A SG11201502778T A SG 11201502778TA SG 11201502778T A SG11201502778T A SG 11201502778TA SG 11201502778T A SG11201502778T A SG 11201502778TA
- Authority
- SG
- Singapore
- Prior art keywords
- stratification
- prognosis
- ovarian cancer
- ovarian
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG11201502778TA SG11201502778TA (en) | 2012-10-12 | 2013-10-11 | Method of prognosis and stratification of ovarian cancer |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG2012076915 | 2012-10-12 | ||
SG11201502778TA SG11201502778TA (en) | 2012-10-12 | 2013-10-11 | Method of prognosis and stratification of ovarian cancer |
PCT/SG2013/000436 WO2014058394A1 (en) | 2012-10-12 | 2013-10-11 | Method of prognosis and stratification of ovarian cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201502778TA true SG11201502778TA (en) | 2015-05-28 |
Family
ID=54141527
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201703022SA SG10201703022SA (en) | 2012-10-12 | 2013-10-11 | Method of prognosis and stratification of ovarian cancer |
SG11201502778TA SG11201502778TA (en) | 2012-10-12 | 2013-10-11 | Method of prognosis and stratification of ovarian cancer |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201703022SA SG10201703022SA (en) | 2012-10-12 | 2013-10-11 | Method of prognosis and stratification of ovarian cancer |
Country Status (5)
Country | Link |
---|---|
US (1) | US20150267259A1 (en) |
EP (1) | EP2906724A4 (en) |
CN (1) | CN104854247A (en) |
SG (2) | SG10201703022SA (en) |
WO (1) | WO2014058394A1 (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9953417B2 (en) * | 2013-10-04 | 2018-04-24 | The University Of Manchester | Biomarker method |
CN108091398B (en) * | 2016-11-21 | 2022-03-04 | 医渡云(北京)技术有限公司 | Patient grouping method and device |
CN107050469B (en) * | 2017-01-18 | 2019-07-30 | 中国科学院昆明动物研究所 | The purposes of people's NCAPH gene |
CN108229099B (en) * | 2017-12-29 | 2021-01-05 | 北京科迅生物技术有限公司 | Data processing method, data processing device, storage medium and processor |
CN108470111B (en) * | 2018-05-09 | 2022-01-18 | 中国科学院昆明动物研究所 | Stomach cancer personalized prognosis evaluation method based on polygene expression profile |
CN108647493B (en) * | 2018-05-09 | 2022-01-18 | 中国科学院昆明动物研究所 | Individualized prognosis evaluation method for renal clear cell carcinoma |
WO2019226514A2 (en) * | 2018-05-21 | 2019-11-28 | Nanostring Technologies, Inc. | Molecular gene signatures and methods of using same |
US11462325B2 (en) * | 2018-09-29 | 2022-10-04 | Roche Molecular Systems, Inc. | Multimodal machine learning based clinical predictor |
GB201902653D0 (en) * | 2019-02-27 | 2019-04-10 | Univ Oxford Innovation Ltd | High-grade serous ovarian carcinoma (HGSOC) |
CN110452982A (en) * | 2019-05-08 | 2019-11-15 | 中山大学孙逸仙纪念医院 | Breast cancer circulating tumor cell miRNA and EMT markers in detecting kit and its application |
CN110551819B (en) * | 2019-08-23 | 2023-05-16 | 伯克利南京医学研究有限责任公司 | Application of ovarian cancer prognosis related genes |
CN111705060B (en) * | 2020-06-29 | 2023-07-28 | 北京大学深圳医院 | shRNA of NCAPD2 gene and application thereof |
CN111781364B (en) * | 2020-08-25 | 2023-07-21 | 北京信诺卫康科技有限公司 | Wnt7a and HE4 combined as early ovarian cancer biomarker and kit |
CN112289450B (en) * | 2020-12-25 | 2021-05-18 | 浙江高美生物科技有限公司 | Prediction system for prognosis survival period of intrahepatic cholangiocellular carcinoma patient |
CN113774135B (en) * | 2021-09-17 | 2024-03-08 | 广东省人民医院 | Group of markers for predicting prognosis of high-grade serous ovarian cancer and application thereof |
CN114381529B (en) * | 2022-03-16 | 2022-06-10 | 上海晟燃生物科技有限公司 | Application of ACTR10 and CA125 combination in ovarian cancer detection and kit |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008095096A2 (en) * | 2007-01-31 | 2008-08-07 | Immune Disease Institute | Let-7 microrna and mimetics thereof as therapeutics for cancer |
US8030060B2 (en) * | 2007-03-22 | 2011-10-04 | West Virginia University | Gene signature for diagnosis and prognosis of breast cancer and ovarian cancer |
WO2010083312A2 (en) * | 2009-01-14 | 2010-07-22 | The Trustees Of The University Of Pennsylvania | Micro-rna biomarker in cancer |
US9953129B2 (en) * | 2011-09-23 | 2018-04-24 | Agency For Science, Technology And Research | Patient stratification and determining clinical outcome for cancer patients |
-
2013
- 2013-10-11 EP EP13845996.1A patent/EP2906724A4/en not_active Withdrawn
- 2013-10-11 WO PCT/SG2013/000436 patent/WO2014058394A1/en active Application Filing
- 2013-10-11 SG SG10201703022SA patent/SG10201703022SA/en unknown
- 2013-10-11 SG SG11201502778TA patent/SG11201502778TA/en unknown
- 2013-10-11 CN CN201380065419.9A patent/CN104854247A/en active Pending
- 2013-10-11 US US14/435,155 patent/US20150267259A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2014058394A1 (en) | 2014-04-17 |
EP2906724A1 (en) | 2015-08-19 |
US20150267259A1 (en) | 2015-09-24 |
EP2906724A4 (en) | 2016-12-14 |
SG10201703022SA (en) | 2017-06-29 |
CN104854247A (en) | 2015-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG10201703022SA (en) | Method of prognosis and stratification of ovarian cancer | |
IL276488A (en) | Method of predicting breast cancer prognosis | |
HK1206431A1 (en) | Method for the prognosis and treatment of cancer metastasis | |
HK1219763A1 (en) | Compositions and methods for cancer prognosis | |
HK1212256A1 (en) | Anti-mcam antibodies and associated methods of use -mcam | |
IL237791B (en) | Method of treating cancer | |
HK1204302A1 (en) | Compositions and methods for cancer immunotherapy | |
EP2922861A4 (en) | Biomarker compositions and methods | |
PL2908823T3 (en) | Methods of treating cancer | |
SG11201503893RA (en) | Method of treating cancer | |
HK1197273A1 (en) | Methods and materials related to ovarian cancer | |
HK1206414A1 (en) | Biomarkers for gastric cancer and uses thereof | |
HK1259001A1 (en) | Methods of prognosis and diagnosis of cancer | |
HK1215193A1 (en) | Methods of treating ovarian cancer with dll4 antagonists dll4 | |
HK1205558A1 (en) | Methods and biomarkers for detection and prognosis of cervical cancer | |
EP2895206A4 (en) | Method of treating cancer | |
GB2510539B (en) | Biomarkers of cancer | |
HK1200502A1 (en) | Method for determining prognosis of prostate cancer in a subject | |
EP2812694A4 (en) | Assays and methods for the diagnosis of ovarian cancer | |
EP2709730A4 (en) | Treatment and prognosis of cancer | |
IL239426A0 (en) | Biomarker methods and compositions | |
EP2916200A4 (en) | Semi-compact keyboard and method therefor | |
ZA201503833B (en) | Method of hemoglobin-f determination | |
GB201222952D0 (en) | Treatent of cancer |